Reynolds syndrome is a rare autoimmune condition defined by the overlap of two distinct diseases: primary biliary cholangitis (a chronic liver disease) and limited cutaneous systemic sclerosis (a form of scleroderma that primarily affects the skin and blood vessels). The syndrome was first described as a recognized clinical entity because these two conditions appear together far more often than chance alone would explain, suggesting a shared autoimmune mechanism driving both.
The Two Diseases Behind the Syndrome
To understand Reynolds syndrome, it helps to understand its two components separately.
Primary biliary cholangitis (PBC) is a condition in which the immune system gradually attacks the small bile ducts inside the liver. Bile builds up, damaging liver tissue over time. Early on, this can cause intense itching (pruritus), fatigue, and dry eyes or mouth. As it progresses, it can lead to scarring of the liver and eventually cirrhosis. PBC is diagnosed in part by testing for a specific antibody called antimitochondrial antibody (AMA-M2), which is considered a hallmark marker of the disease.
Limited cutaneous systemic sclerosis, sometimes called CREST syndrome, is a form of scleroderma that primarily affects the skin of the fingers, hands, face, and forearms. CREST is actually an acronym for its five hallmark features: calcium deposits under the skin (appearing as firm white or yellow bumps on joints, fingertips, and the face), Raynaud’s phenomenon (painful spasms in small blood vessels that turn fingers and toes blue), esophageal dysfunction (difficulty swallowing), sclerodactyly (skin on the fingers becomes so tight and rigid it restricts bending), and telangiectasias (small dilated blood vessels visible under the skin as red or purple marks). A key antibody associated with this form of scleroderma is the anticentromere antibody.
In Reynolds syndrome, a patient has both conditions simultaneously. The signs and symptoms therefore include those of both PBC and limited cutaneous systemic sclerosis, though not every feature of each disease appears in every patient.
Who Gets Reynolds Syndrome
Reynolds syndrome is rare, and precise prevalence figures are difficult to pin down because it sits at the intersection of two already uncommon diseases. Liver involvement is generally uncommon in scleroderma patients, but when it does occur, PBC is the most frequent liver-related association. Both PBC and limited scleroderma are far more common in women than in men, so Reynolds syndrome follows the same pattern. Most cases are diagnosed in middle-aged women.
There is evidence of shared autoimmune tendencies between the two diseases. Patients who test positive for anticentromere antibodies (linked to scleroderma) are substantially more likely to also carry antimitochondrial antibodies (linked to PBC) compared to other autoimmune patients. In one study, the AMA-M2 positivity rate was about 26% in anticentromere-positive patients versus roughly 7% in a comparison group. This overlap in antibody profiles helps explain why the two conditions cluster together.
How It’s Diagnosed
Diagnosis typically involves recognizing features of both diseases in the same patient. If you already have a scleroderma diagnosis and develop unexplained itching, fatigue, or abnormal liver function tests, your doctor may suspect PBC and order antibody testing. The reverse path also happens: a patient being treated for PBC may develop Raynaud’s phenomenon or skin tightening, prompting evaluation for scleroderma.
Blood tests play a central role. Antimitochondrial antibodies point toward PBC, while anticentromere antibodies point toward limited scleroderma. Elevated markers of bile duct damage on liver function panels add further evidence. In some cases, a liver biopsy may be used to confirm the stage of bile duct disease, though this is not always necessary if the antibody picture is clear.
Symptoms to Watch For
Because Reynolds syndrome combines two diseases, the symptom picture can be wide-ranging. On the scleroderma side, you might experience cold sensitivity in your fingers and toes with color changes (white, blue, then red as blood flow returns), thickening and tightening of the skin on your hands and face, difficulty swallowing, small visible blood vessels on the skin, and hard calcium bumps near your joints or fingertips.
On the liver side, persistent itching that worsens at night is one of the earliest and most bothersome symptoms. Fatigue that feels out of proportion to your activity level is also common. Dry eyes and a dry mouth can occur as well. As liver disease advances, more serious signs like jaundice (yellowing of the skin and eyes) or fluid retention may develop, though many patients are diagnosed and treated well before reaching that stage.
Treatment and Management
There is no single cure for Reynolds syndrome. Instead, treatment targets each component disease separately. For the PBC portion, the standard approach is ursodeoxycholic acid, a medication that helps bile flow more normally through the liver and slows the progression of bile duct damage. This drug is taken long-term, and its effectiveness is monitored through regular blood tests tracking liver enzyme levels.
Managing the scleroderma component involves a combination of approaches. Physical therapy helps maintain finger mobility and joint function as skin tightens. Raynaud’s episodes can be reduced by keeping hands and feet warm and, when necessary, using medications that relax blood vessels. Esophageal symptoms are often managed with acid-reducing medications and dietary adjustments.
One complication in treating Reynolds syndrome is that some medications used for scleroderma symptoms can stress the liver. When both conditions coexist, doctors monitor liver enzymes closely and only use potentially liver-affecting drugs when enzyme levels remain within a safe range. This balancing act between treating skin and vascular symptoms without worsening liver function is a defining challenge of managing the syndrome.
Long-Term Outlook and Complications
The prognosis for Reynolds syndrome depends largely on how well each component disease is controlled. PBC, when caught early and treated with ursodeoxycholic acid, progresses slowly in most patients. Many people live for decades without developing cirrhosis. Left untreated, however, ongoing bile duct destruction can eventually lead to liver failure.
On the scleroderma side, the limited cutaneous form generally has a better outlook than more widespread forms of the disease. The most serious potential complication is pulmonary hypertension, a condition where blood pressure rises in the vessels leading to the lungs. This can develop independently from the scleroderma, from the liver disease, or from both. Pulmonary hypertension is the complication doctors watch for most carefully, as it significantly affects quality of life and long-term survival.
Regular monitoring is the cornerstone of living with Reynolds syndrome. This typically means periodic liver function tests, lung function assessments, and echocardiograms to check heart and lung pressures. Because the syndrome involves chronic autoimmune activity, new symptoms should be evaluated promptly, as autoimmune diseases can sometimes trigger additional conditions over time.